GlassScriptPhysician profile
Nabeel Umer Moon
NPI 1982109310
$4,188.83
in general payments reported to CMS, 2019-2025
16 companies · $890 in 2025
The $890 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $370 · 2023: $371 · 2024: $2,557 · 2025: $890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,263 · Travel and Lodging: $1,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,263.34 |
| Travel and Lodging | $1,555.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,840.07 | 2024-2025 | Axios, General - Therapies, Apollo Esg System |
| Genzyme Corporation | $276.97 | 2022-2024 | |
| Abbvie INC. | $274.41 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $262.96 | 2022-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.07 | 2022-2023 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $86.83 | 2023 | Dupixent |
| Ardelyx, INC. | $69.66 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.18 | 2025 | Jardiance |
| Novo Nordisk INC | $38.20 | 2022-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $34.87 | 2024 | Omvoh |
| Janssen Scientific Affairs, LLC | $26.66 | 2025 | Tremfya |
| Janssen Biotech, INC. | $24.92 | 2025 | Tremfya |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Shield Therapeutics INC | $24.47 | 2025 | |
| Pentax of America, INC. | $22.88 | 2025 | Pentax Medical, Inspira, C2 Cryoballoon |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $16.20 | 2023 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nabeel Moon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.